Unlock the Future of Drug Development
with AI

Discover How AI/ML are Revolutionizing Clinical Trials and Navigate Regulatory Expectations
The comprehensive white paper, “Artificial Intelligence in Drug Development: Navigating Emerging Regulatory Expectations and Enhancing Clinical Trials,” authored by Patrick Brady, PharmD, explores the transformative potential of AI and machine learning (ML) in clinical trials. This paper provides valuable insights into how global health authorities are shaping the regulatory framework and offers practical guidance on leveraging AI/ML to improve trial efficiency, design, and outcomes. The valuable learnings include:

  • Regulatory Insights: Understand the current regulatory landscape with insights from the FDA and EMA on the use of AI/ML in clinical trials.
  • Risk-Based Approaches: Learn how to implement risk management plans to mitigate potential risks and ensure the safety and reliability of AI/ML applications.
  • Strategic AI/ML Applications: Discover practical applications of AI/ML in clinical trials, including patient recruitment, dose optimization, and participant stratification.
LET’S TALK

Go beyond the download: request a consultation with a dedicated sales specialist.
By selecting this box, I consent to receiving marketing communications and information about IQVIA's offering by email.

Copyright © 2026 IQVIA Holdings Inc. and its affiliates. All rights reserved. Privacy Statement

DO NOT SELL MY PERSONAL INFORMATION